[{"id":"cd6bbcee-c7e4-4f63-a4d9-478a5b04000b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06136988","created_at":"2023-11-19T12:16:11.097Z","updated_at":"2024-07-02T16:35:28.828Z","phase":"Phase 1/2","brief_title":"A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.","source_id_and_acronym":"NCT06136988","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Enshuxing (enlonstobart) • albumin-bound docetaxel (CPO100)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 129","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-11-18"},{"id":"a4ab15d0-16d6-4472-a500-892e161496fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04886700","created_at":"2021-05-14T12:52:35.943Z","updated_at":"2024-07-02T16:36:20.376Z","phase":"Phase 2","brief_title":"Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer","source_id_and_acronym":"NCT04886700","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enshuxing (enlonstobart)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 07/31/2021","start_date":" 07/31/2021","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2021-11-22"},{"id":"6d58f2b1-4611-48af-86d9-5b426fa6afe2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05068141","created_at":"2021-10-05T20:00:16.991Z","updated_at":"2024-07-02T16:36:22.965Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT05068141","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PD-L1 negative • ER negative • PGR negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PD-L1 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Enshuxing (enlonstobart)"],"overall_status":"Recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2021-10-15"},{"id":"67cbf364-5178-48ac-a2d4-4cfc52c84dd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05009953","created_at":"2021-08-18T15:53:39.772Z","updated_at":"2024-07-02T16:36:24.253Z","phase":"Phase 2","brief_title":"Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer","source_id_and_acronym":"NCT05009953","lead_sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • leucovorin calcium • Enshuxing (enlonstobart) • irinotecan liposomal"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2021-09-20"},{"id":"21c46c94-55f0-4de3-b632-30f9e8aa31a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04983550","created_at":"2021-07-30T17:55:00.289Z","updated_at":"2024-07-02T16:36:27.196Z","phase":"Phase 2","brief_title":"Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC","source_id_and_acronym":"NCT04983550","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enshuxing (enlonstobart)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2021-07-30"},{"id":"80d64d88-7b7f-4c88-a23e-128e49df49a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03852823","created_at":"2021-01-18T19:01:01.230Z","updated_at":"2024-07-02T16:36:30.899Z","phase":"Phase 1","brief_title":"Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours","source_id_and_acronym":"NCT03852823","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" EGFR • PD-L1 • ALK • MSI","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • ALK mutation","tags":["EGFR • PD-L1 • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enshuxing (enlonstobart)"],"overall_status":"Recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 05/23/2019","start_date":" 05/23/2019","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2021-04-30"}]